AU2013349239B2 - Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides - Google Patents

Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides Download PDF

Info

Publication number
AU2013349239B2
AU2013349239B2 AU2013349239A AU2013349239A AU2013349239B2 AU 2013349239 B2 AU2013349239 B2 AU 2013349239B2 AU 2013349239 A AU2013349239 A AU 2013349239A AU 2013349239 A AU2013349239 A AU 2013349239A AU 2013349239 B2 AU2013349239 B2 AU 2013349239B2
Authority
AU
Australia
Prior art keywords
leu
ser
pro
ala
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013349239A
Other languages
English (en)
Other versions
AU2013349239A1 (en
Inventor
Ahuva BAR-ILAN
Oren HERSHKOVITZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Opko Biologics Ltd
Original Assignee
Opko Biologics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opko Biologics Ltd filed Critical Opko Biologics Ltd
Publication of AU2013349239A1 publication Critical patent/AU2013349239A1/en
Application granted granted Critical
Publication of AU2013349239B2 publication Critical patent/AU2013349239B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
AU2013349239A 2012-11-20 2013-11-20 Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides Active AU2013349239B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261728662P 2012-11-20 2012-11-20
US61/728,662 2012-11-20
PCT/IL2013/050960 WO2014080401A2 (en) 2012-11-20 2013-11-20 Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides

Publications (2)

Publication Number Publication Date
AU2013349239A1 AU2013349239A1 (en) 2015-07-09
AU2013349239B2 true AU2013349239B2 (en) 2018-04-12

Family

ID=50776635

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013349239A Active AU2013349239B2 (en) 2012-11-20 2013-11-20 Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides

Country Status (20)

Country Link
US (1) US9808534B2 (enExample)
EP (2) EP3848386A1 (enExample)
JP (2) JP6416106B2 (enExample)
KR (2) KR102202255B1 (enExample)
CN (3) CN114317505A (enExample)
AU (1) AU2013349239B2 (enExample)
BR (2) BR112015011583B1 (enExample)
CA (1) CA2891393A1 (enExample)
CL (1) CL2015001347A1 (enExample)
EA (1) EA033788B1 (enExample)
ES (1) ES2882890T3 (enExample)
HU (1) HUE055348T2 (enExample)
IL (1) IL264700B (enExample)
MX (1) MX363326B (enExample)
MY (1) MY172997A (enExample)
PE (2) PE20210171A1 (enExample)
PL (1) PL2922867T3 (enExample)
PT (1) PT2922867T (enExample)
SG (3) SG10202010383YA (enExample)
WO (1) WO2014080401A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US12203113B2 (en) 2009-07-09 2025-01-21 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
DK3326642T3 (da) * 2012-02-14 2021-02-22 Opko Biologics Ltd Langtidsvirkende koagulationsfaktorer og brugen deraf
US9522945B2 (en) * 2012-04-19 2016-12-20 Opko Biologics Ltd. Long-acting oxyntomodulin variants and methods of producing same
SG10202010383YA (en) 2012-11-20 2020-11-27 Opko Biologics Ltd Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
CN105461810A (zh) * 2014-08-31 2016-04-06 复旦大学 一种长效的重组人粒细胞集落刺激因子的及其制备方法和用途
JP7000153B2 (ja) * 2014-12-10 2022-01-19 オプコ バイオロジクス リミテッド 長時間作用性ｃｔｐ修飾成長ホルモンポリペプチドを生成する方法
EA201791275A1 (ru) * 2014-12-10 2017-12-29 Опко Байолоджикс Лтд. Способы получения ctp-модифицированных полипептидов длительного действия
IL301728A (en) * 2015-06-19 2023-05-01 Opko Biologics Ltd Long-term coagulation factors and methods for their preparation
CN106397571A (zh) * 2015-07-31 2017-02-15 李金松 一种新型羧基末端肽及长效白介素7
CN106397570B (zh) * 2015-07-31 2019-11-15 袁武梅 一种羧基末端肽及长效干扰素
HUE064463T2 (hu) 2016-07-11 2024-03-28 Opko Biologics Ltd Hosszantartó hatású VII. koagulációs faktor és az elõállítására vonatkozó eljárások
CN107759696A (zh) * 2016-08-19 2018-03-06 安源医药科技（上海）有限公司 人白介素7融合蛋白及其制备方法
CN106279437B (zh) * 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
CN114667293A (zh) * 2019-09-24 2022-06-24 Mvrix株式会社 抗病毒活性增强的纳米穿孔器
WO2021078834A1 (en) * 2019-10-22 2021-04-29 Genethon Chimeric acid-alpha glucosidase polypeptides and uses thereof

Family Cites Families (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
JPS5781447A (en) 1980-11-11 1982-05-21 Toyo Jozo Co Ltd Human chorionic gonadotropic hormone c-terminal fragment
US4853332A (en) 1982-10-19 1989-08-01 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
DE3421468A1 (de) 1984-06-08 1985-12-19 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4911691A (en) 1984-09-21 1990-03-27 Menlo Care, Inc. Assembly for adminstering IV solution
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
ATE141646T1 (de) 1986-04-09 1996-09-15 Genzyme Corp Genetisch transformierte tiere, die ein gewünschtes protein in milch absondern
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
EP0374257B1 (en) 1988-05-06 1994-08-31 Toray Industries, Inc. STABLE INTERFERON $g(b) COMPOSITION
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
ATE148171T1 (de) 1989-02-21 1997-02-15 Univ Washington Modifizierte formen von fortpflanzungshormonen
US5338835A (en) 1989-02-21 1994-08-16 Washington University CTP-extended form of FSH
US6225449B1 (en) 1991-10-04 2001-05-01 Washington University Hormone analogs with multiple CTP extensions
US5792460A (en) * 1989-02-21 1998-08-11 Washington University Modified glycoprotein hormones having a CTP at the amino terminus
US5705478A (en) 1989-02-21 1998-01-06 Washington University Covalently linked β subunits of the glycoprotein hormones as antagonists
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US7217689B1 (en) 1989-10-13 2007-05-15 Amgen Inc. Glycosylation analogs of erythropoietin
US5126324A (en) 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US6028177A (en) 1991-10-04 2000-02-22 Washington University Methods of detecting single-chain forms of the glycoprotein hormone quartet
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
ATE187740T1 (de) 1993-04-20 2000-01-15 Univ Washington Modifizierte proteine und peptide enthaltende pharmazeutische mittel
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5605976A (en) 1995-05-15 1997-02-25 Enzon, Inc. Method of preparing polyalkylene oxide carboxylic acids
US6737515B2 (en) 1993-11-19 2004-05-18 Washington University Follicle stimulating hormone-glycosylation analogs
US6238890B1 (en) 1994-02-18 2001-05-29 Washington University Single chain forms of the glycoprotein hormone quartet
US5935924A (en) 1994-04-15 1999-08-10 Genentech, Inc. Treatment of congestive heart failure
US5541110A (en) 1994-05-17 1996-07-30 Bristol-Myers Squibb Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica
MX9601320A (es) 1994-08-12 1997-05-31 Univ Washington Formas de cadena unica de cuarteto de hormona de glicoproteina.
US6083725A (en) 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
US20050032211A1 (en) 1996-09-26 2005-02-10 Metabogal Ltd. Cell/tissue culturing device, system and method
TW518235B (en) 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
US6310183B1 (en) 1997-09-10 2001-10-30 Novo Nordisk A/S Coagulation factor VIIa composition
US6103501A (en) 1997-11-17 2000-08-15 Washington University Single chain glycoprotein hormones comprising two β and one α subunits and recombinant production thereof
CN100480266C (zh) 1998-10-16 2009-04-22 拜奥根Idec马萨诸塞公司 干扰素-β融合蛋白及用途
US6514729B1 (en) 1999-05-12 2003-02-04 Xencor, Inc. Recombinant interferon-beta muteins
JO2291B1 (en) 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythropoietin derivatives
WO2001056579A1 (en) * 2000-02-04 2001-08-09 Esperion Therapeutics Inc. Methods for treating alzheimer's disease
US20020127652A1 (en) 2000-02-11 2002-09-12 Schambye Hans Thalsgard Follicle stimulating hormones
US7094566B2 (en) 2000-03-16 2006-08-22 Amgen Inc., IL-17 receptor like molecules and uses thereof
US20030036181A1 (en) 2000-06-30 2003-02-20 Okkels Jens Sigurd Peptide extended glycosylated polypeptides
US7118737B2 (en) 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
AU2000202A (en) 2000-10-31 2002-05-15 Pr Pharmaceuticals Inc Methods and compositions for enhanced delivery of bioactive molecules
JP4344136B2 (ja) 2000-11-10 2009-10-14 エフ・ホフマン−ラ・ロシュ・リミテッド アポリポタンパク質類似体
JP4409135B2 (ja) 2000-12-01 2010-02-03 武田薬品工業株式会社 生理活性物質含有製剤の製造法
EP1346722B1 (en) 2000-12-01 2008-12-10 Takeda Pharmaceutical Company Limited Method for producing preparation containing bioactive substance
ES2311560T3 (es) 2000-12-07 2009-02-16 Eli Lilly And Company Proteinas de fusion glp-1.
ATE320449T1 (de) 2000-12-11 2006-04-15 Cheil Jedang Corp Fusionsprotein mit verbesserter in vivo erythropoietinwirkung
KR101229995B1 (ko) * 2000-12-11 2013-02-06 씨제이 주식회사 생체내 에리스로포이에틴 활성이 증진된 융합단백질
JP5160005B2 (ja) 2000-12-28 2013-03-13 武田薬品工業株式会社 徐放性製剤
US8637077B2 (en) 2000-12-28 2014-01-28 Takeda Pharmaceutical Company Limited Sustained-release preparation
US6987172B2 (en) 2001-03-05 2006-01-17 Washington University In St. Louis Multifunctional single chain glycoprotein hormones comprising three or more β subunits
US6887462B2 (en) 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
AU2002338436A1 (en) 2001-04-25 2002-11-05 Hernan F. Acevedo Hcg formulation
US6824769B2 (en) 2001-08-28 2004-11-30 Vertex Pharmaceuticals Incorporated Optimal compositions and methods thereof for treating HCV infections
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
CN100347306C (zh) 2001-10-29 2007-11-07 克鲁塞尔荷兰公司 生产具有预定的翻译后修饰的蛋白质的方法和手段
KR100467751B1 (ko) * 2001-12-03 2005-01-24 씨제이 주식회사 생체내 에리스로포이에틴 활성이 증진된 융합단백질
PT1463751E (pt) 2001-12-21 2013-08-26 Human Genome Sciences Inc Proteínas de fusão de albumina
US7081446B2 (en) 2002-01-31 2006-07-25 The Trustees Of Columbia University In The City Of New York Long-acting follicle stimulating hormone analogues and uses thereof
US7173113B2 (en) 2002-01-31 2007-02-06 The Trustees Of Columbia University In The City Of New York Long-acting hormone and growth factor compositions and uses thereof
GB0206048D0 (en) 2002-03-14 2002-04-24 Croda Int Plc Use
WO2003094858A2 (en) 2002-05-13 2003-11-20 Modigenetech Ltd. Ctp-extended erythropoietin
US20070298041A1 (en) 2002-06-28 2007-12-27 Tomlinson Ian M Ligands That Enhance Endogenous Compounds
BR0312947A (pt) 2002-07-17 2007-07-10 Biogen Idec Inc terapias para insuficiência renal empregando-se interferon-beta
US7459435B2 (en) 2002-08-29 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
US8129330B2 (en) 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US7459436B2 (en) 2002-11-22 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
CA2516339A1 (en) 2003-02-19 2004-09-02 Takeda Pharmaceutical Company Limited Dispersing agent for sustained-release preparation
JP4683319B2 (ja) 2003-02-19 2011-05-18 武田薬品工業株式会社 徐放性製剤用の分散剤
CA2521784C (en) 2003-04-08 2012-03-27 Yeda Research And Development Co. Ltd. Reversible pegylated drugs
NZ542586A (en) 2003-04-09 2009-11-27 Biogenerix Ag Method of forming a covalent conjugate between a G-CSF peptide and PEG
WO2005035761A1 (en) 2003-10-16 2005-04-21 Compugen Ltd. Splice variants of preproglucagon, glucagon-like peptide-1 and oxyntomodulin
WO2005047319A2 (en) 2003-11-12 2005-05-26 The University Of Georgia Research Foundation, Inc. Dna sequence and expressed recombinant glycoproteins related to feline thyrotropin
JP2007514673A (ja) 2003-12-19 2007-06-07 エフ．ホフマン−ラ　ロシュ　アーゲー 慢性炎症性腸疾患の際の鉄分布障害の処置におけるエリスロポエチンの使用
US7425539B2 (en) 2004-03-19 2008-09-16 Baxter International Inc. Factor IXa for the treatment of bleeding disorders
US20080206270A1 (en) 2004-07-08 2008-08-28 Minev Boris R Enhancing Class I Antigen Presentation With Synthetic Sequences
BRPI0514396A2 (pt) 2004-08-17 2009-05-12 Csl Behring Gmbh polipeptìdeos dependentes de vitamina k modificada
EP1802645A4 (en) 2004-09-27 2009-01-14 Cornell Res Foundation Inc BIFUNCTIONAL RECOMBINANT PROTEIN OF HUMAN LUTROPINE RECEPTOR AND HUMAN CHRONIC GONADOTROPHIN B UNIT AND USES THEREOF
EP1841452B8 (en) 2004-10-08 2014-06-11 Domantis Limited Single domain antibodies against tnfr1 and methods of use therefor
GB0521621D0 (en) 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
EP1728798A1 (en) 2005-06-01 2006-12-06 ZLB Behring GmbH Coagulation factor X polypeptides with modified activation properties
CA2612063A1 (en) 2005-06-13 2006-12-21 Imperial Innovations Limited Oxyntomodulin analogues and their effects on feeding behaviour
US8759290B2 (en) 2005-10-18 2014-06-24 Biocon Limited Oral glucagon-like peptide conjugates for metabolic diseases
US8304386B2 (en) * 2006-02-03 2012-11-06 Prolor Biotech, Inc. Long-acting growth hormone and methods of producing same
WO2007092252A2 (en) 2006-02-03 2007-08-16 Modigene Inc Long-acting polypeptides and methods of producing same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US8048848B2 (en) * 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8759292B2 (en) * 2006-02-03 2014-06-24 Prolor Biotech, Llc Long-acting coagulation factors and methods of producing same
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US8476234B2 (en) 2006-02-03 2013-07-02 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
EP2471810A1 (en) 2006-02-22 2012-07-04 Merck Sharp & Dohme Corporation Oxyntomodulin derivatives
TW200806317A (en) 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
WO2007149406A2 (en) 2006-06-19 2007-12-27 Nautilus Technology Llc Modified coagulation factor ix polypeptides and use thereof for treatment
AT505262A1 (de) 2007-06-12 2008-12-15 Apeiron Biolog Forschungs Und Rekombinantes ace2 polypeptid
US7741074B2 (en) 2007-12-05 2010-06-22 Novozymes, Inc. Polypeptides having endoglucanase activity and polynucleotides encoding same
AU2009279090A1 (en) 2008-08-06 2010-02-11 Novo Nordisk Health Care Ag Conjugated proteins with prolonged in vivo efficacy
EP2898900B1 (en) 2008-09-19 2017-11-15 Nektar Therapeutics Polymer conjugates of ziconotide
AU2010217045B2 (en) 2009-02-27 2013-02-07 Guhring Ohg Modular automated tool dispenser
US8828953B2 (en) 2009-04-20 2014-09-09 NaZura BioHealth, Inc. Chemosensory receptor ligand-based therapies
DE102009031992A1 (de) 2009-07-06 2011-01-13 Paul Hartmann Ag Vorrichtung zur Unterdrucktherapie von Wunden
JO2976B1 (en) 2009-12-22 2016-03-15 ايلي ليلي اند كومباني Axentomodulin polypeptide
KR101382593B1 (ko) 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
EP2714070B1 (en) 2011-06-02 2024-03-20 OPKO Biologics Ltd. Long-acting glp-1/glucagon receptor agonists
US9522945B2 (en) * 2012-04-19 2016-12-20 Opko Biologics Ltd. Long-acting oxyntomodulin variants and methods of producing same
PE20150181A1 (es) 2012-06-04 2015-02-28 Opko Biolog Ltd Variantes de oxm pegilada
SG10202010383YA (en) 2012-11-20 2020-11-27 Opko Biologics Ltd Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Kontermann R.E. "Strategies for extended serum half-life of protein therapeutics" Current Opinion in Biotechnology (2011) 22: 868–876 *

Also Published As

Publication number Publication date
SG10202010383YA (en) 2020-11-27
MY172997A (en) 2019-12-18
IL264700B (en) 2022-03-01
PT2922867T (pt) 2021-10-29
EP2922867A4 (en) 2016-08-03
KR20210016042A (ko) 2021-02-10
PL2922867T3 (pl) 2021-12-06
US9808534B2 (en) 2017-11-07
JP2016501198A (ja) 2016-01-18
SG11201503879QA (en) 2015-06-29
SG10201610223PA (en) 2017-02-27
KR20150110486A (ko) 2015-10-02
BR122020018510B1 (pt) 2023-03-14
JP2019038812A (ja) 2019-03-14
HUE055348T2 (hu) 2021-11-29
WO2014080401A3 (en) 2014-09-25
CN112661863A (zh) 2021-04-16
ES2882890T3 (es) 2021-12-03
PE20151087A1 (es) 2015-08-28
BR112015011583A2 (enExample) 2017-08-15
CN114317505A (zh) 2022-04-12
MX363326B (es) 2019-03-20
CA2891393A1 (en) 2014-05-30
US20140316112A1 (en) 2014-10-23
EP3848386A1 (en) 2021-07-14
EA033788B1 (ru) 2019-11-26
WO2014080401A2 (en) 2014-05-30
AU2013349239A1 (en) 2015-07-09
EP2922867A2 (en) 2015-09-30
KR102341581B1 (ko) 2021-12-21
MX2015006302A (es) 2016-03-11
EP2922867B1 (en) 2021-07-21
CN105121459A (zh) 2015-12-02
EA201590994A1 (ru) 2016-03-31
JP6416106B2 (ja) 2018-10-31
PE20210171A1 (es) 2021-01-29
CL2015001347A1 (es) 2015-09-04
BR112015011583B1 (pt) 2023-03-14
KR102202255B1 (ko) 2021-01-13

Similar Documents

Publication Publication Date Title
KR102341581B1 (ko) 생식샘자극 호르몬 카복시 말단 펩타이드들과 부착하여 폴리펩타이드들의 유체역학적 부피를 증가시키는 방법
JP6153930B2 (ja) 持続型成長ホルモンおよびそれを生成する方法
KR101950961B1 (ko) 장기-작용성 응고 인자 및 이의 제조 방법
US20100081614A1 (en) Long-acting growth hormone and methods of producing same
KR20150008137A (ko) 지속성 옥신토모둘린 변이체 및 이의 생산 방법
US20140371144A1 (en) Long-acting growth hormone and methods of producing same
TWI893324B (zh) 長效型多肽及其生產和給藥的方法
HK40056885A (en) Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
HK40073071A (en) Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
HK40047241A (en) Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
HK40008897B (en) Long-acting growth hormone and methods of producing same
HK1234320A1 (en) Long-acting factor vii coagulation factors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)